+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antiviral Therapeutics Market - Global Forecast 2026-2032- Product Image
Antiviral Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Antiviral Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5264367
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antiviral Therapeutics Market is projected to reach USD 95.06 Billion in 2026. It is expected to continue growing at a CAGR of 8.57%, reaching USD 157.02 Billion by 2032.

Antiviral therapeutics remain a critical pillar of global infectious disease management, spanning HIV, hepatitis B, hepatitis C, influenza, herpesviruses, SARS-CoV-2, and emerging viral threats. The antiviral therapeutics landscape is shaped by clinically validated drug classes such as nucleoside and nucleotide analogs, protease inhibitors, polymerase inhibitors, integrase inhibitors, entry inhibitors, and combination regimens that reduce viral replication, limit disease progression, and support public health preparedness.

Demand is reinforced by verified disease burden reported by global health agencies, including WHO-recognized ongoing challenges in HIV, viral hepatitis, seasonal influenza, and epidemic-prone respiratory viruses. As diagnostics, surveillance, and rapid treatment pathways improve, antiviral drugs are increasingly positioned not only as acute-care interventions but also as long-term tools for outbreak resilience, hospital capacity protection, antimicrobial stewardship-adjacent strategies, and population-level disease control.

Transformative Shifts in the Antiviral Therapeutics Landscape

The antiviral therapeutics landscape is moving from reactive treatment models toward faster, more targeted, and more scalable care. Direct-acting antivirals for hepatitis C demonstrated that short-course curative therapy is clinically viable, while modern HIV therapy confirmed the value of durable combination regimens, adherence innovation, resistance monitoring, and guideline-driven chronic disease management.

COVID-19 accelerated structural change by normalizing emergency authorizations, adaptive clinical trial designs, test-to-treat models, and government-supported procurement. Industry competition is now focused on oral antivirals, long-acting formulations, pan-viral mechanisms, improved safety profiles, resistance barriers, and medicines that can be deployed rapidly across outpatient settings before disease progression increases hospitalization risk.

Cumulative Impact of Artificial Intelligence on Antiviral Innovation

Artificial intelligence is becoming a cumulative force across antiviral drug discovery, development, and lifecycle management. AI-enabled protein modeling, virtual screening, molecular design, and predictive toxicology help researchers prioritize targets and compounds more efficiently, especially when viral mutation rates and resistance pathways require rapid iteration.

Beyond discovery, AI supports clinical trial site selection, patient stratification, pharmacovigilance signal detection, real-world evidence generation, and supply-demand planning. Its value is strongest when paired with validated laboratory assays, human clinical expertise, transparent governance, and regulatory-grade data quality, ensuring that speed does not compromise safety, efficacy, reproducibility, or patient trust.

Key Regional Insights Across Global Antiviral Demand

Asia-Pacific is central to antiviral therapeutics because of high patient volumes, expanding healthcare access, and strong manufacturing capacity across India and China, with Japan, South Korea, and Australia contributing advanced research, surveillance systems, and regulatory maturity. North America remains a leading commercialization and innovation hub, supported by public biomedical research, established regulatory pathways, clinical trial infrastructure, and pandemic preparedness funding.

Europe benefits from coordinated regulatory review, strong public health systems, vaccination and surveillance networks, and established clinical research capacity, while Latin America, led by Brazil and Mexico, is focused on broader access, public procurement, infectious disease monitoring, and affordability. The Middle East, particularly Gulf economies, is investing in health security, specialty care, and centralized procurement, whereas Africa represents a high-need region where HIV, hepatitis, respiratory outbreaks, and emerging infection control depend on affordability, donor-supported programs, diagnostics, local capacity building, and resilient supply chains.

Key Group Insights Shaping Antiviral Therapeutics Strategy

ASEAN markets are gaining relevance as infectious disease surveillance, generic medicine access, and regional health cooperation improve across Southeast Asia, particularly for respiratory viruses, hepatitis, HIV, and dengue-related preparedness. The GCC is advancing antiviral readiness through healthcare infrastructure investment, centralized procurement, digital health adoption, and national health security strategies, while the European Union is strengthening coordinated response capabilities through joint procurement, regulatory alignment, health emergency preparedness, and cross-border surveillance initiatives.

BRICS countries are influential because they combine large patient populations, active clinical research, and major pharmaceutical manufacturing bases, particularly in China, India, and Brazil, with strategic focus on access, self-reliance, and domestic innovation. The G7 continues to shape global antiviral priorities through research funding, regulatory science, pandemic preparedness commitments, and support for global health programs, while NATO members increasingly view antiviral stockpiles, biosecurity, medical logistics, and continuity of care as components of health resilience and national security.

Key Country Insights for Antiviral Therapeutics Expansion

The United States leads in antiviral research funding, biotechnology innovation, regulatory approvals, clinical trial activity, and commercial uptake, while Canada emphasizes evidence-based reimbursement, public health preparedness, and equitable access. Mexico and Brazil are important access markets where public procurement, local epidemiology, manufacturing policy, and affordability shape antiviral adoption. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced healthcare systems with strong regulatory, reimbursement, and clinical research capabilities, while Russia maintains domestic production priorities and strategic interest in infectious disease control.

China and India are essential to global antiviral supply, with China expanding novel drug development, clinical research capacity, and domestic regulatory modernization, while India serves as a major producer of generics and active pharmaceutical ingredients supporting global access. Japan prioritizes high-quality clinical evidence, antiviral preparedness, and care for an aging population; Australia supports advanced surveillance and regional health security across the Indo-Pacific; and South Korea combines biotechnology growth, manufacturing capability, rapid diagnostics, and digital health infrastructure to support antiviral innovation.

Actionable Recommendations for Antiviral Industry Leaders

Industry leaders should prioritize diversified antiviral portfolios that address both chronic viral diseases and acute outbreak-prone infections. Investment should focus on oral agents, long-acting delivery systems, combination therapy, resistance-informed development, and broad-spectrum candidates with credible clinical, manufacturing, and regulatory pathways.

Executives should also strengthen diagnostic partnerships, test-to-treat distribution, AI governance, pharmacovigilance, and manufacturing redundancy. Competitive advantage will increasingly depend on the ability to balance premium innovation with equitable access, align with public health agencies, support evidence-based reimbursement, and build supply chains resilient enough to support both routine care and emergency demand surges.

Research Methodology and Evidence Framework

This executive summary is developed through a structured secondary research approach using verified public health, regulatory, clinical, and industry sources. Evidence inputs include global health agency updates, regulatory authority approvals and guidance, clinical trial registries, peer-reviewed literature, treatment guidelines, public procurement information, and recognized surveillance data.

Insights are triangulated across disease burden, therapeutic standards, pipeline trends, geographic access factors, procurement behavior, manufacturing capacity, and policy developments. The methodology prioritizes data-backed interpretation, avoids unsupported market claims, and frames strategic conclusions around observable therapeutic, regulatory, clinical, and public health evidence.

Conclusion: Strategic Outlook for Antiviral Therapeutics

Antiviral therapeutics are entering a more strategic phase defined by precision drug design, faster outbreak response, stronger surveillance, and broader access expectations. Established therapy areas such as HIV, hepatitis, influenza, and herpesviruses continue to support sustained clinical need, while COVID-19 has permanently elevated the importance of scalable outpatient antivirals and pandemic preparedness.

Future leadership will depend on scientific differentiation, AI-enabled development, resistance management, regional access planning, and reliable manufacturing. Organizations that integrate clinical innovation with public health alignment, regulatory discipline, and equitable access will be best positioned to support long-term value in antiviral drugs and global infectious disease control.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Antiviral Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Polymerase Inhibitors
7.3. Protease Inhibitors
7.4. Integrase Inhibitors
7.5. Fusion Inhibitors
8. Antiviral Therapeutics Market, by Route Of Administration
8.1. Introduction
8.2. Inhalation
8.3. Injectable
8.4. Oral
8.5. Topical
9. Antiviral Therapeutics Market, by Virus Type
9.1. Introduction
9.2. HIV
9.3. Hepatitis Viruses
9.4. Influenza
9.5. Herpes Viruses
9.6. Respiratory Viruses
10. Antiviral Therapeutics Market, by Route of Administration
10.1. Introduction
10.2. Oral
10.3. Intravenous
10.4. Topical
10.5. Nasal
11. Antiviral Therapeutics Market, by Treatment Type
11.1. Introduction
11.2. Curative Therapies
11.3. Maintenance Therapies
11.4. Prophylactic Therapies
12. Antiviral Therapeutics Market, by End-User
12.1. Introduction
12.2. Hospitals
12.3. Specialty Clinics
12.4. Homecare Settings
12.5. Public Health Programs
13. Antiviral Therapeutics Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Antiviral Therapeutics Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Antiviral Therapeutics Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. AbbVie Inc.
17.3. Alkem Laboratories Limited
17.4. AstraZeneca PLC
17.5. Atea Pharmaceuticals, Inc.
17.6. Aurobindo Pharma Limited
17.7. Bristol-Myers Squibb Company
17.8. Cipla Ltd.
17.9. Cocrystal Pharma, Inc.
17.10. Daiichi Sankyo Company, Ltd.
17.11. Dr. Reddy’s Laboratories Ltd.
17.12. Eli Lilly and Company
17.13. F. Hoffmann-La Roche Ltd.
17.14. Gilead Sciences, Inc.
17.15. GlaxoSmithKline plc
17.16. Hetero Labs Limited
17.17. Johnson & Johnson Services Inc.
17.18. Merck & Co., Inc.
17.19. Novartis AG
17.20. Pfizer Inc.
17.21. Sanofi S.A.
17.22. Sun Pharmaceutical Industries Limited
17.23. Syngene International Limited
17.24. Takeda Pharmaceutical Company Limited
17.25. Themis Medicare Ltd.
17.26. Venatorx Pharmaceuticals, Inc.
17.27. Viatris Inc.
17.28. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL ANTIVIRAL THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANTIVIRAL THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL POLYMERASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL POLYMERASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL POLYMERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL INTEGRASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL INTEGRASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL INTEGRASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL FUSION INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL FUSION INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL FUSION INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL INHALATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL HIV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL HIV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL HIV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL HEPATITIS VIRUSES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL HEPATITIS VIRUSES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL HEPATITIS VIRUSES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL HERPES VIRUSES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL HERPES VIRUSES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL HERPES VIRUSES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL RESPIRATORY VIRUSES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL RESPIRATORY VIRUSES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL RESPIRATORY VIRUSES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL NASAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL NASAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL CURATIVE THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL CURATIVE THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL CURATIVE THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL MAINTENANCE THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL MAINTENANCE THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL MAINTENANCE THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PROPHYLACTIC THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL PROPHYLACTIC THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL PROPHYLACTIC THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PUBLIC HEALTH PROGRAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL PUBLIC HEALTH PROGRAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL PUBLIC HEALTH PROGRAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 89. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 91. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 92. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 93. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 94. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 96. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 98. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 99. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 100. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 101. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 102. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 103. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 105. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 106. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 107. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 108. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 109. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 110. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 112. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 113. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 114. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 115. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 116. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 117. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 119. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 120. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 121. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 122. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 123. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 127. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 128. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 129. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 130. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 131. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 132. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 134. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 135. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 136. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 137. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 138. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 141. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 142. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 144. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 146. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 147. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 148. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 149. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 150. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 151. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 152. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 153. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 154. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 155. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 156. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 157. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 158. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 159. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 160. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 162. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 163. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 164. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 165. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 166. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 168. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 169. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 170. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 171. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 172. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 173. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 174. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 175. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 176. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 177. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 178. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 179. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 180. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 181. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 182. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 183. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 184. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 185. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 186. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 187. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 188. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 189. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 190. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 191. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 192. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 193. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 194. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 195. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 196. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 197. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 198. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 199. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 200. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 201. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 202. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 203. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 204. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 205. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 206. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 207. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 208. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 209. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 210. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 211. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 212. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 213. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 214. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 215. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 216. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 217. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 218. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 219. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 220. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 221. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 222. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 223. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 224. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 225. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 226. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 227. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 228. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 229. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 230. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 231. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 232. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 233. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 234. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 235. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 236. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 237. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 238. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 239. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 240. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 241. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 242. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 243. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 244. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 245. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 246. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 247. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 248. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 249. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 250. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 251. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 252. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 253. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 254. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 255. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 256. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 257. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 258. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 259. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 260. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 261. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 262. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 263. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 264. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 265. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 266. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 267. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 268. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 269. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY VIRUS TYPE, 2017-2032 (USD MILLION)
TABLE 270. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 271. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 272. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 273. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 274. GLOBAL ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Alkem Laboratories Limited
  • AstraZeneca PLC
  • Atea Pharmaceuticals, Inc.
  • Aurobindo Pharma Limited
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Cocrystal Pharma, Inc.
  • Daiichi Sankyo Company, Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Syngene International Limited
  • Takeda Pharmaceutical Company Limited
  • Themis Medicare Ltd.
  • Venatorx Pharmaceuticals, Inc.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 95.06 Billion
Forecasted Market Value ( USD ) by 2032 $ 157.02 Billion
Compound Annual Growth Rate8.5%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Direct-acting Antiviral Drug Market - Global Forecast 2026-2032 - Product Image

Direct-acting Antiviral Drug Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Direct Acting Antivirals Market - Global Forecast 2026-2032 - Product Image

Direct Acting Antivirals Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Antiviral Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035 - Product Image

Antiviral Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

  • Report
  • 139 Pages
  • Global
From
Antivirals Market Report 2026 - Product Image

Antivirals Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Oral Antivirals Market - Global Strategic Business Report - Product Image

Oral Antivirals Market - Global Strategic Business Report

  • Report
  • 380 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.